profit from every $100 of sales.
$0$100
Catalyst Pharmaceuticals
We have no price for Catalyst Pharmaceuticals since 21 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$31.49+0.00% today
+54.4% since Oct 8, 25
1-year low $20.311-year high $31.50
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $17.99 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Catalyst Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $214 million in 2022 to $589 million in 2025, with $214 million of profit last year.
SalesProfit
Catalyst Pharmaceuticals handed back 12% of the cash it generated last year.
Buybacks $25M
Free cash flow 2025$209M
Bought back its own shares$25M
Paid as dividends–
Cash vs. debt$709M vs. $3M
Catalyst Pharmaceuticals vs. similar companies
Catalyst Pharmaceuticals grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Catalyst Pharmaceuticals | 18.0× · Fair price | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Catalyst Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 214 | 398 | 492 | 589 | |
| 180 | 346 | 423 | 502 | |
| 102 | 87 | 195 | 258 | |
| 103 | 120 | 233 | 296 | |
| 83 | 71 | 164 | 214 | |
| 0.75 | 0.63 | 1.31 | 1.68 | |
| 83.9% | 86.9% | 86.0% | 85.2% | |
| 47.5% | 21.8% | 39.7% | 43.8% | |
| 38.8% | 17.9% | 33.3% | 36.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 376 | 470 | 851 | 1,104 |
| Cash | 298 | 138 | 518 | 709 |
| Total debt | 4 | 4 | 3 | 3 |
| Total liabilities | 75 | 82 | 124 | 150 |
| 300 | 388 | 728 | 954 | |
| 111 | 114 | 125 | 127 | |
| 26.4% | 17.5% | 21.1% | 21.3% | |
| 27.7% | 18.4% | 22.5% | 22.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 116 | 144 | 240 | 209 | |
| 0 | 82 | 1 | 0 | |
| 116 | 62 | 239 | 209 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 25 | |
| 8 | 14 | 22 | 25 |
Valuation
- 18.0×
- 16.7×
- 0.58
- 3.8×
- 6.5×
- 18.5×
- 10.6×
- 5.4%
- 5.6%
- 0.0%
Profitability
- 85.2%
- 43.8%
- 36.4%
- 52.5%
- 19.7%
- 21.8%
- 23.7%
- 19.3%
- 26.4%
- 1.9%
Growth
- +40.1%
- +30.8%
- −12.8%
- –
- +4.3%
Financial health
- -2.4×
- 0.00
- 0.2%
- –
- 7.10
- 6.84
- 0.52
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 7%of 958
Top 3%of 888
Top 30%of 600
Top 14%of 889
Top 21%of 987
What analysts expect
- Average price target
- $33.00
- Range
- $33.00 – $33.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 0.74 | 0.64 | +15.6% |
| Feb 25, 2026 | 0.68 | 0.42 | +61.9% |
| Nov 5, 2025 | 0.68 | 0.51 | +33.3% |
| Aug 6, 2025 | 0.68 | 0.58 | +17.2% |
| May 7, 2025 | 0.68 | 0.53 | +28.3% |
| Feb 26, 2025 | 0.70 | 0.32 | +118.7% |
| Nov 6, 2024 | 0.57 | 0.49 | +16.3% |
| Aug 7, 2024 | 0.56 | 0.42 | +33.3% |
News
Zcash Is Getting a Major Upgrade in November. Could This Be a Catalyst for Further ZEC Price Gains?Yahoo Finance · Nov 4, 2026Could Apple's Latest iPhone Be Its Biggest Growth Catalyst in Years?Yahoo Finance · Nov 1, 2026IBM Continues to Plug Along, but Its Quantum Computing Bet Could Be the Real CatalystYahoo Finance · Oct 26, 2026Prediction: One Major Catalyst Could Send Alphabet Stock to New HighsYahoo Finance · Oct 19, 2026Trumpflation and a Surprise Catalyst Are the 2 Biggest Threats to the Trump Bull MarketYahoo Finance · Oct 18, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
82Pass
Benjamin Graham
75Pass
Philip Fisher
95Pass
Peter Lynch
100Pass
Joel Greenblatt
59No pass
Charlie Munger
92Pass
Terry Smith
91Pass
Questions about Catalyst Pharmaceuticals
Is Catalyst Pharmaceuticals a good stock to buy?
A strong, very profitable business at a fair price. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Catalyst Pharmaceuticals AI analysis
What does Catalyst Pharmaceuticals do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It is in Biotechnology, based in Coral Gables, FL, United States, with 182 employees.
Does Catalyst Pharmaceuticals pay a dividend?
No. Catalyst Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $25.3 million to shareholders by buying back its own shares.
Is Catalyst Pharmaceuticals stock halal?
Yes. Catalyst Pharmaceuticals passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
Who are Catalyst Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Catalyst Pharmaceuticals's.
Prices: daily closes to Jul 21, 2026. Fundamentals: company reports via invest-like data.